Skip to main content

PhaseBio Pharmaceuticals Inc

PHASDelisted Dec 21, 2022
Industry
Pharmaceutical Preparations
SEC CIK
0001169245

PhaseBio Pharmaceuticals Inc was delisted on Dec 21, 2022; its insiders filed their last Form 4 on May 19, 2023; 39 institutions reported holding it in 13F filings for Q3 2022, worth $3.90M in total; no superinvestor held it.

Q3 2022 vs. Q2 2022

How the institutions holding PhaseBio Pharmaceuticals Inc changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of PHAS: Q2 2022 compared with Q3 2022
MeasureQ2 2022Q3 2022Change
Holders5039−11
Shares23.4M22.2M−1.25M (−5.4%)
Value$14.1M$3.90M−$10.2M (−72.3%)

New holders (1)

Institutions that held PhaseBio Pharmaceuticals Inc at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to PHAS in Q3 2022
InstitutionSharesValue% of portfolio
Simplex Trading, LLC3,317$00.00%

Sold out (12)

Institutions that held PhaseBio Pharmaceuticals Inc at the end of Q2 2022 and filed for Q3 2022 without it.

Institutions that sold out of PHAS in Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
CHI Advisors LLC750,000$450.0K
New Legacy Group, LLC240,575$144.0K
Marshall Wace, LLP123,039$73.0K
Citadel Advisors LLC107,953$65.0K
Prudential Financial Inc44,100$26.0K
Virtu Financial LLC31,852$19.0K
Millennium Management LLC13,501$8.00K
Two Sigma Securities, LLC12,845$8.00K
Two Sigma Advisers, LP12,700$8.00K
UBS Group AG9,830$6.00K
Toronto Dominion Bank4,670$3.00K
Curi Capital823$0